Baseline characteristics of participants of the PACT study included in the cost-effectiveness analyses*
| Breast cancer | Colon cancer | |||
|---|---|---|---|---|
| Intervention (N=87) | Control (N=78) | Intervention (N=14) | Control (N=15) | |
| Age (years) | 50.0±7.9 | 49.4±7.6 | 57.4±11.2 | 59.1±8.9 |
| Educational status | ||||
| Low | 2 (2%) | 12 (15%) | 1 (7%) | 2 (13%) |
| Medium | 40 (46%) | 33 (42%) | 6 (43%) | 4 (27%) |
| High | 43 (49%) | 33 (42%) | 7 (50%) | 9 (60%) |
| Missing | 2 (2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Marital status | ||||
| Alone | 17 (20%) | 14 (18%) | 4 (29%) | 5 (33%) |
| Married/living together | 70 (81%) | 64 (82%) | 10 (71%) | 10 (67%) |
| Gender | ||||
| Male | 0 (0%) | 0 (0%) | 7 (50%) | 11 (73%) |
| Female | 87 (100%) | 78 (100%) | 7 (50%) | 4 (27%) |
| Tissue expander | ||||
| Yes | 9 (10%) | 8 (10%) | – | – |
| No | 78 (90%) | 70 (90%) | – | – |
| Radiotherapy | ||||
| Yes | 60 (69%) | 52 (67%) | 1 (7%) | 1 (7%) |
| No | 27 (31%) | 26 (33%) | 13 (93%) | 14 (93%) |
| Chemotherapy | ||||
| FEC/DOC | 54 (62%) | 53 (68%) | – | – |
| AC/paclitaxel trastuzumab | 16 (18%) | 10 (13%) | – | – |
| TAC | 17 (20%) | 15 (19%) | – | – |
| CAPOX | – | – | 13 (93%) | 15 (100%) |
| Capecitabine mono | – | – | 1 (7%) | 0 (0%) |
| Tumour receptor status | ||||
| Triple- | 20 (23%) | 8 (10%) | – | – |
| Her2Neu+&ER or PR+ | 10 (12%) | 11 (14%) | – | – |
| Her2Neu+&ER and PR− | 10 (12%) | 2 (3%) | – | – |
| Her2Neu−&ER or PR+ | 47 (54%) | 57 (73%) | – | – |
| Menopausal status | ||||
| Postmenopausal | 39 (45%) | 23 (30%) | 3 (21%) | 3 (20%) |
| Premenopausal | 40 (46%) | 53 (68%) | 3 (21%) | 0 (0%) |
| Not applicable (male) | – | – | 7 (50%) | 11 (73%) |
| Missing | 8 (9%) | 2 (3%) | 1 (7%) | 1 (7%) |
| Body mass index (kg/m2) | 25.3±4.2 | 25.8±4.5 | 26.8±4.4 | 26.0±2.9 |
*Continuous values are given as mean±SD and categorical values in number of patients (%).
DOC, Docetaxel; AC, Adriamycin and Cyclophosphamide; FEC, 5-fluorouracil, Epirubicin and Cyclophosphamide; TAC, Docetaxel, Adriamycin, Cyclophosphamide.